Patents Assigned to HiberCell, Inc.
  • Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
    Patent number: 11919902
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, and n are described herein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 5, 2024
    Assignee: HiberCell, Inc.
    Inventors: Johan Lindström, Lars Boukharta Persson, Madeleine Livendahl, Jenny Viklund, Tobias Ginman, Rickard Forsblom, Fredrik Rahm, Edward A. Kesicki, Kannan Karukurichi Ravi, Eugene R. Hickey, Markus K. Dahlgren, Aleksey I. Gerasyuto
  • Beta glucan immunopharmacodynamics
    Patent number: 11815435
    Abstract: This disclosure provides, in one aspect, dosing strategies for soluble ?-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble ?-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-?-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: November 14, 2023
    Assignee: HiberCell, Inc.
    Inventors: Nandita Bose, Nadine Ottoson, Ben Harrison, Jamie Lowe, Mark Uhlik, Jeremy Graff, Richard Huhn
  • Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
    Patent number: 11667651
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 6, 2023
    Assignee: HiberCell, Inc.
    Inventors: Johan Lindström, Lars Boukharta Persson, Jenny Viklund, Edward A. Kesicki, Eugene R. Hickey, Markus K. Dahlgren, Aleksey I. Gerasyuto
  • Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
    Patent number: 11584763
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 21, 2023
    Assignee: HiberCell, Inc.
    Inventors: Johan Lindström, Lars Boukharta Persson, Jenny Viklund, Rickard Forsblom, Tobias Ginman, Edward A. Kesicki, Eugene R. Hickey, Markus K. Dahlgren, Aleksey I. Gerasyuto
  • Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
    Patent number: 11535635
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: December 27, 2022
    Assignee: HiberCell, Inc.
    Inventors: Johan Lindström, Lars Boukharta Persson, Jenny Viklund, Rickard Forsblom, Tobias Ginman, Edward A. Kesicki, Eugene R. Hickey, Markus K. Dahlgren, Aleksey I. Gerasyuto
  • Chromenopyrimidine derivatives as phosphatidylinsitol phosphate kinase inhibitors
    Patent number: 11498929
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: November 15, 2022
    Assignee: HiberCell, Inc.
    Inventor: Edward A. Kesicki
  • Methods for identifying beta-glucan binding to immune cells
    Patent number: 11229701
    Abstract: This disclosure describes, in one aspect, a method for identifying ?-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble ?-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble ?-glucan to bind to the immune cells, and detecting soluble ?-glucan bound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of ?-glucan, and co-administering to the subject a soluble ?-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: January 25, 2022
    Assignee: HiberCell, Inc.
    Inventors: William J. Grossman, Mary A. Antonysamy, Richard M. Walsh, Mariana I. Nelson, Nandita Bose, Michael E. Danielson, Kyle S. Michel